^
BIOMARKER:

PD-L1 underexpression

i
Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
Related biomarkers:
PD-L1 underexpression
Melanoma
nivolumab / relatlimab
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 1 week - (New A1)
PD-L1 underexpression
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive
:
A2
ESMO 2022 - 3 weeks - (New B)
PD-L1 underexpression
Lung Non-Squamous Non-Small Cell Cancer
MEDI5752
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-L1 underexpression
Melanoma
ipilimumab
Sensitive
:
A1
PD-L1 underexpression
Melanoma
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 underexpression
Lung Adenocarcinoma
nivolumab + ipilimumab
Sensitive
:
A2
PD-L1 underexpression
Non Small Cell Lung Cancer
nivolumab
Resistant
:
B
PD-L1 underexpression
Non Small Cell Lung Cancer
durvalumab + CP-675206
Sensitive
:
B
PD-L1 underexpression
Gastric Adenocarcinoma
Immunotherapy
Resistant
:
B
PD-L1 underexpression
Esophageal Adenocarcinoma
Immunotherapy
Resistant
:
B
PD-L1 underexpression
Lung Non-Small Cell Squamous Cancer
nivolumab + ipilimumab
Sensitive
:
C1
PD-L1 underexpression
Non Small Cell Lung Cancer
pembrolizumab
Sensitive
:
C2
PD-L1 underexpression
Non Small Cell Lung Cancer
camrelizumab
Sensitive
:
C3
PD-L1 underexpression
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
C3
PD-L1 underexpression
Non Small Cell Lung Cancer
ipilimumab + cemiplimab
Sensitive
:
C3
PD-L1 underexpression
Urothelial Cancer
nivolumab + IPI-549
Sensitive
:
C3
PD-L1 underexpression
Mantle Cell Lymphoma
ibrutinib
Resistant
:
C3
PD-L1 underexpression
Cutaneous T-cell Lymphoma
durvalumab + lenalidomide
Sensitive
:
C3
PD-L1 underexpression
Triple Negative Breast Cancer
atezolizumab + RG6180
Sensitive
:
C3
PD-L1 underexpression
Acute Myelogenous Leukemia
XmAb14045
Sensitive
:
C3
PD-L1 underexpression
Malignant Pleural Mesothelioma
PD1 inhibitor
Resistant
:
C3
PD-L1 underexpression
Squamous Cell Carcinoma of Head and Neck
cetuximab sarotalocan
Sensitive
:
C3
PD-L1 underexpression
Non Small Cell Lung Cancer
avelumab + VX15
Sensitive
:
C3
PD-L1 underexpression
Gastric Adenocarcinoma
toripalimab + surufatinib
Sensitive
:
C3
PD-L1 underexpression
Esophageal Squamous Cell Carcinoma
toripalimab + surufatinib
Sensitive
:
C3
PD-L1 underexpression
Colorectal Cancer
atezolizumab + RG6180
Sensitive
:
C3
PD-L1 underexpression
Melanoma
atezolizumab + RG6180
Sensitive
:
C3
PD-L1 underexpression
Non Small Cell Lung Cancer
atezolizumab + RG6180
Sensitive
:
C3
PD-L1 underexpression
Non Small Cell Lung Cancer
durvalumab
Resistant
:
C3
PD-L1 underexpression
Renal Cell Carcinoma
PD-L1 inhibitor
Sensitive
:
C3
PD-L1 underexpression
Hepatocellular Cancer
nivolumab
Sensitive
:
C3
PD-L1 underexpression
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Sensitive
:
C3
PD-L1 underexpression
Non Small Cell Lung Cancer
gemcitabine
Sensitive
:
C3
PD-L1 underexpression
Triple Negative Breast Cancer
carboplatin + paclitaxel
Resistant
:
C3
PD-L1 underexpression
Squamous Cell Carcinoma of Head and Neck
VX15
Sensitive
:
C3